Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease: Results from a population-based follow-up study

BMJ Open

Volumn 4, Issue 2, 2014, Pages

  Hsieh, Chuan Fa ^a,b   Huang, Song Lih ^a   Chen, Chien Lung ^b   Chen, Wei Ta ^b   Chang, Huan Cheng ^b,c   Yang, Chen Chang ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Taiwan Landseed Hospital   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; BUPRENORPHINE; CODEINE; CREATININE; ERYTHROPOIETIN; MORPHINE; NALBUPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; TRAMADOL; ARISTOLOCHIC ACID I; HERBACEOUS AGENT;

ADULT; AGED; ARTICLE; CHINESE MEDICINE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DATA BASE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH INSURANCE; NEOPLASM; PRESCRIPTION; SENSITIVITY ANALYSIS; SURVIVAL RATE; TAIWAN; EPIDEMIOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ARISTOLOCHIC ACIDS; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 84896828856     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004033     Document Type: Article

References (33)

1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-72.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
3. Burrows NR, Li Y, Williams DE. Racial and ethnic differences in trends of end-stage renal disease: United States, 1995 to 2005. Adv Chronic Kidney Dis 2008;15:147-52. (Pubitemid 351335412)
4. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91. (Pubitemid 23048140)
5. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010;102:179-86.
6. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173-82. (Pubitemid 351890412)
7. Hsieh CF, Huang SL, Chen CL, et al. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med 2012;55:155-9.
8. Wojcikowski K, Johnson DW, Gobe G. Herbs or natural substances as complementary therapies for chronic kidney disease: ideas for future studies. J Lab Clin Med 2006;147:160-6.
9. National Health Research Institutes. National Health Insurance Research Databases. http://w3.nhri.org.tw/nhird//date-01.html (accessed 13 Aug 2013).
10. Gau CS, Chang IS, Lin Wu FL, et al. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidemiol Drug Saf 2007;16:86-95.
11. Lee EK, Cham TM, Tseng PL. Using the pharmacoepidemiology approach to evaluate the first-year posttransplantation ambulatory health care cost from the Longitudinal Health Insurance Database (2001 to 2006) in Taiwan. Transplant Proc 2010;42:957 -60.
12. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55.
13. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology (Carlton) 2009;14:227-34.
14. Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51.
15. Food and Drug Administration, U.S. Aristolochic Acid: Listing of Botanical Ingredients of Concern. http://www.fda.gov/Food/ RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ucm095283.htm (accessed 20 Nov 2013).
16. Bureau of National Health Insurance, Ministry of Health and Welfare. Query of Drug reimbursed by National Health Insurance, 2012 [in Chinese]. http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu-id=713&webdata-id= 3510&WD-ID=851 (accessed 16 Aug 2013).
17. Committee on Chinese Medicine and Pharmacy, Ministry of Health and Welfare. Unified formulas of Chinese Herbal Medicine. http://www.mohw.gov.tw/ CHT/DOCMAP/DM1.aspx?f-list-no=758&fod-list-no=3918 (accessed 29 Jan 2014).
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373 -83.
19. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-9. (Pubitemid 24373619)
20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
21. Peng A, Gu Y, Lin SY. Herbal treatment for renal diseases. Ann Acad Med Singapore 2005;34:44-51. (Pubitemid 40379972)
22. Li Y, Shen L, Chen R, et al. Effects of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection on the levels of main platelet thrombin receptors in chronic haemodialysis patients. Chin J Integr Med 2011;17:625-30.
23. Meng L, Qu L, Tang J, et al. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, enhanced nitric oxide production in obstructed rat kidney. Vascul Pharmacol 2007;47:174-83. (Pubitemid 47103267)
24. Meng LQ, Tang JW, Wang Y, et al. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol 2011;162:1805-18.
25. Grzegorczyk K, Krajewska M, Weyde W, et al. Gender and kidney diseases: the clinical importance and mechanisms of modifying effects. Postepy Hig Med Dosw (Online) 2011;65:849-57.
26. Rodriguez-Puyol D. The aging kidney. Kidney Int 1998;54:2247-65.
27. Ravera M, Re M, Deferrari L, et al. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006;17: S98-103.
28. Fioretto P, Bruseghin M, Berto I, et al. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol 2006;17:S86-9.
29. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
30. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280-7.
31. Kurth T, Glynn RJ, Walker AM, et al . Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003;42:234-44. (Pubitemid 36944429)
32. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004;164:1519-24. (Pubitemid 38970471)
33. Chen YH, Lu FL, Liu YC, et al. Survey on heavy metals in raw materials of traditional Chinese medicine. Ann Rep Food Drug Res 2012;3:373-84.